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Abstract
Background: Balancing the rights and obligations of custodians and applicants in relation to access to biobanks is
of utmost importance to guarantee trust and confidence. This study aimed to reveal which issues divide different
stakeholders in an attempt to determine the rights and/or obligations held on human biological materials (HBM)
and data.
Methods: Twenty-eight informants in the Benelux and Scandinavia were interviewed in order to capture the
perspectives of experts and stakeholders in relation to the rights and obligations held by custodians and applicants
with respect to access to HBM and data.
Results: There was no consensus among the informants on whether the custodian of a biobank should decide
upon the scientific merits and the utility of an access request. Nearly all informants agreed that a new request or an
amendment to the initial request has to be submitted when an applicant wants to use leftover HBM in a new or
follow-up project. Several informants felt that it might be justified to charge higher access fees to external or
industrial applicants that did not contribute (directly or indirectly) to the collection of HBM and data. Most
informants agreed that a custodian of a biobank could request the sharing and return of research results. It was
furthermore argued that some of the benefits of research projects should be fed back into biobanks.
Conclusions: The interviews revealed a rather complex web of rights and obligations allocated to the custodian
and the applicant in relation to access to HBM and data stored in biobanks. Some rights and obligations are
negotiated on a case-by-case basis, while others are stipulated in access arrangements. We did find a consensus on
the attribution of certain general rights to the custodians and the applicant.
Background
Researchers need to be able to access efficiently different
collections of HBM and data [1, 2]. However, biobanks
and biobank networks, as custodians of HBMs and asso-
ciated data, need to exercise a certain control on the ac-
cess to and the use of their collections in order to
guarantee their long-time sustainability and the scien-
tific, ethical and legal correctness of their use [2–5]. In
addition, custodians need to ensure that access requests
comply with the applicable legislation and the conditions
stipulated in the consent of the donors/patients [6, 7].
Balancing the rights and obligations of custodians and
applicants in relation to access to biobanks is of the ut-
most importance to guarantee trust and confidence.
After many years of discussions there is still no answer
to the question whether ‘ownership’ rights can be held
or claimed in relation to HBMs (and associated data)
collected and used for research purposes [2, 8–12]. Con-
sidering the uncertain status of the ‘ownership’ of HBM,
some authors suggested applying instead the concept of
‘custodianship’ [13], ‘charitable trust’ [14] or ‘stewardship’
[15]. However, replacing the concept of ownership with
new concepts does not automatically provide an answer
to the practical question as to which rights and obliga-
tions can be held on HBM and data, as rightfully indi-
cated by J. Conley e.a. [16]: “When the National Cancer
Institute announces that (…) it will rely on the poorly de-
fined state-law concept of “custodianship,” it seems less a
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solution than an invitation to even greater inefficiency.
The same applies to Winickoff and Winickoff ’s “charit-
able trust” analogy and the “stewardship” proposal ad-
vanced by Fullerton et al.: because of the legal
imprecision of their central concepts and the apparent
complexity of adapting them to biobanking, they are, on
a practical level, likely to introduce more problems than
they solve” [16].
Previous empirical research on biobanks focused on
consent, public perception and participation in biobanks,
etc. [17–22]. Few research projects have focused on cus-
todianship of HBM stored in biobanks [23–25].
The qualitative study described in this paper, has
looked into the following research questions:
 What are the different perspectives held by
stakeholders in relation to the (bundle of ) rights and
obligations held by custodians and researchers
applying for access to HBM and data?
 Which topics divide the different stakeholders in
trying to determine the (bundle of ) rights and
obligations held by custodians and applicants?
Methods
Definitions
In this article the term ‘access arrangements’ can be de-
fined as ‘guidelines, best practices, opinions, policies,
agreements, etc. containing rules on access to and use of
HBM and data collections stored within biobanks’ (a
similar definition of access arrangements is used by S.
Fortin et al. [4] and the OECD [26]). An ‘access commit-
tee’ can be defined as ‘a committee established by a bio-
bank to decide upon a request for access to the
collection of HBM and/or data stored in the biobank.’
The ‘biobank’ refers to ‘a (single) infrastructure dedi-
cated to the storage and provision of HBMs or data or
both for research purposes.’ The term ‘biobank network’
refers to ‘a group of institutions that freely assume the
commitment to collaborate in the domain of biobanking
and that (often) share the same procedures and quality
policies, and that are (or might be) helped by a central hub
for coordination in terms of service’ [5]. ‘Custodianship’ can
be defined as the ‘caretaking responsibility for HBM and
data that starts at the planning of a biobank initiative, prior
to the collection, and continues through research use to
final dissemination of research results’ (a slightly adapted
version of the definition used by R. Yassin et al.[13] and the
National Cancer Institute [27]). The ‘custodian’ is defined –
by the authors – as the person(s) or entity – such as the
biobank manager – and/or the access committee – and/or
the institution that exercises custodianship on HBM and
data stored in a particular biobank. The term ‘ownership’
can be defined as ‘the ultimate and exclusive right con-
ferred by a lawful claim or title, and subject to certain
restrictions to enjoy, occupy, possess, rent, sell, use, give
away, or even destroy an item of property’ [28]. Finally, the
term ‘researcher’ refers to researchers both from the public
and private sector.
Data collection: key informant interviews
Data were collected via key informant, face-to-face (and
some Skype-based) interviews. All informants confirmed
their participation in an email. The study did not require
an ethical approval, since it is non-experimental and we
did not interview human research subjects (i.e., patients
or donors) or health care providers. We furthermore did
not obtain identifiable private/personal information from
research subjects. This was confirmed by an analysis of
the applicable regulations in the concerned countries.
At the beginning of the interview the informants were
asked whether they objected to the fact that the inter-
views would be recorded and transcribed ad verbatim.
None of the informants made any objection and all of
them answered our questions voluntarily which confirms
their consent to participate.
The aim of the interviews was to gain an in-depth un-
derstanding of how access to data is arranged in the
daily practice of biobanks and biobank networks. A
qualitative research method was chosen to gather infor-
mation on the hopes and concerns of the different stake-
holders in this respect. Semi-structured interviews were
conducted to collect information about a number of
pre-defined topics (enlisted in the interview guide (Add-
itional file 1), at the same time allowing the interviewers
to probe deeper when required. The interview questions
deliberately did not explicitly refer to legal concepts such
as rights and obligations, in order to avoid that the in-
formants would focus their answer on such concepts.
Sampling a strategy for the key informant interviews
Twenty-eight informants in Europe were selected by
means of ‘purposeful/purposive’ sampling [29, 30] and
snowball sampling based on the information provided by
previous informants. The purpose of the sampling was
to capture the different perspectives of 4 distinct cat-
egories of stakeholders – in particular (i) custodians of
biobanks and custodians/representatives of biobank net-
works, (ii) clinical, academic and industrial (research)
applicants, (iii) patient representatives and (iv) represen-
tatives from the pharmaceutical industry. In case infor-
mants fulfilled a double role, the interviewers considered
those double roles focusing on the main role of the in-
formant. We also conducted interviews with legal, eth-
ical and biomedical experts (see Fig. 1). The interviews
with the 4 categories of stakeholders enabled us to ac-
quire a deeper knowledge of the current practices ap-
plied in biobanks and biobank networks and HBM
research in general. Interviewing legal, ethical and
Verlinden et al. BMC Medical Ethics  (2016) 17:15 Page 2 of 10
biomedical experts provided a more in-depth under-
standing of the (ethical, legal and scientific) background
and context in which biobanks operate.
The authors wanted to study variations in perspectives
between different categories of stakeholders and experts
in relation to the rights and obligations held by the cus-
todian and the researcher/applicant. That is why it was
attempted to select at least two informants to represent
each category of stakeholders and experts. The analysis
of the interviews exposed fewer variations in opinions
than expected. It was also noticed that informants repre-
senting the same categories of stakeholders or experts
expressed as much variation in their opinions as infor-
mants who belonged to different categories of stake-
holders or experts. This limited variety in opinions
might be attributed to the fact that some of the topics
discussed during the interview were relatively new for
some informants. For instance, some informants expli-
citly mentioned that they did not yet have a fully devel-
oped opinion on the right to share benefits. It would be
interesting to conduct more interviews and possibly dis-
cover a larger variety of opinions. Unfortunately, due to
time constraints it was not possible to interview add-
itional informants at this stage.
Geographical scope of the interviews
Between October 2013 and January 2014 21 informants
were interviewed in the Benelux. Those countries were
chosen since they host ambitious national biobank initia-
tives such as the Belgian Virtual Tumour Bank and the
Centre for Medical Innovation in Belgium, the Parels-
noer Institute, BBMRI.NL and LifeLines in the
Netherlands and the Integrated BioBank of Luxemburg
(IBBL). In February and March 2014 interviews were
conducted with five informants in Denmark, Sweden
and Norway (see Fig. 2). The Scandinavian countries are
considered pioneers in the development of biobanks and
biobank networks and in epidemiological research [31]
since they have a long tradition of storing HBM and
health data of patients within the framework of health
Fig. 1 Distribution of informants per type of stakeholder or expert
Fig. 2 Geographical distribution of stakeholders and experts. One informant was active in two different countries
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care services and population-based studies. An interest-
ing dimension of the Swedish biobank landscape is the
well-documented cooperation between university bio-
banks and pharmaceutical companies. Additionally, a
representative of an Italian patient organization was
interviewed, since this organization represented patients
with a rare disease. We combined the interviews with
on-site visits of biobanks in Belgium, Denmark and
Sweden to observe their existing policy and practices in
relation to access to biobanks.
Data analysis of the interviews
The data analysis phase consisted of an inductive ana-
lysis according to the Qualitative Analysis Guide of Leu-
ven (QUAGOL) [32]. First, the transcriptions of the
interviews were thoroughly reread by two members of
the research team. Second, a narrative interview report
was drafted to articulate the essence of the interviewee’s
story in answer to the research questions. In a third
stage, conceptual interview schemes were created. In the
fourth stage, the interviews were reread again to verify
whether the content of the conceptual interview
schemes reflected the most important concepts aimed at
in the research questions. The fifth stage consisted of a
comparison of the conceptual interview schemes of the
different interviews to identify and adjust common
themes, concepts or hypotheses.
The actual coding process started with compiling a list
of common concepts (stage six) (see Additional file 2).
The resulting list of concepts was introduced as prelim-
inary codes in the software program ‘Dedoose’. In the
seventh stage, each significant passage of the interview
was linked to one of the concepts of the list. In stage
eight, every concept was analysed through a careful ex-
ploration and study of all citations associated with each
concept. The ninth stage consisted of the extraction of
the essential structure of all the interview data. Based on
this conceptual framework and the in-depth analysis of
stage 8, the authors were able to describe essential find-
ings in answer to the research questions. Significant
quotes were added where necessary and relevant. Finally,
a formal peer debriefing with the other members of the
research team was conducted to discuss and check the
results in answer to the research questions.
Results and discussion
Which committee or body should decide upon access
requests?
The legal framework of many countries – including the
countries that were the object of this study – stipulates
that Research Ethics Committees (RECs) need to provide
an independent opinion on studies on human beings.
More recently, RECs were also given the competence to
provide an opinion on research projects that use HBM
and data stored in biobanks. In some countries RECs are
not expected to review the scientific quality of applica-
tions, while in other countries they are expected to make
such an evaluation.
A previous empirical study [33] revealed that the ma-
jority of biobanks establish their own committees to ex-
ercise a certain control on access to their collections of
HBM and data. Such access committees are established
by a biobank independently from RECs and consist of
different stakeholders involved in the functioning of the
biobank. Authors have stressed the importance of clearly
defining the mandate of access committees and the cri-
teria and procedures used to decide upon an access re-
quest [4, 24, 34]. One will notice in this respect that
article 14 (c) of Recommendation 2006 (4) provides that
one should specify the conditions governing the access
to and the use of HBM. Several authors are in favour of
giving the access committee a rather broad mandate to
decide upon access requests, including the scientific
quality of the research project [35–37]. However, one
author argued that only the biobank – represented by
the custodian – has the right to finally decide on access
request [38].
All interviewed informants agreed that access commit-
tees could decide upon the availability and suitability of
HBM and data for particular research projects and the
impact of the provision of HBM and data on the existing
collection.
However, there was no consensus on whether custo-
dians should decide upon the quality, the usefulness
and the ethical value of research projects. Some infor-
mants were in favour of the idea that the custodian
would follow the advice of a REC or funding body in
this respect.
A custodian of a biobank in the Benelux stated the fol-
lowing in this respect:
“The medical ethics committee is in my opinion not
capable of evaluating the scientific part. It can
evaluate whether something is ethically acceptable;
that is why they are there, not to evaluate the
scientific content. (Free translation by the authors of a
excerpt in Dutch).”
The majority of the informants felt that the custo-
dian – represented by an access committee – could
decide upon the quality and/or scientific, societal
and medical usefulness of the research project that
requests access to the collection of HBM and data.
As to the aspects assessed in such evaluation, these
could include whether the suggested project (i) con-
tributes to the improvement and/or accessibility of
health care; (ii) corresponds to a high medical need;
(iii) adds value to the existing state of science; and
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(iv) might lead to significant new (scientific) insights
or outcome.
A representative of industrial applicants in the Benelux
stated the following in this respect:
“Nobody can predict the future to foresee whether we
will receive within 6 months … a research application
that is more relevant in relation to the (useful)
knowledge that it will provide us. (…). So, I think it
constitutes an important responsibility and a difficult
exercise. (…) If all evaluation criteria are positive, I
feel that one should move ahead (with the project)
(Free translation by the authors of a excerpt in
Dutch)”
Some informants stressed the importance of clarifying
and stimulating the interaction between access commit-
tees and RECs (and possibly also funding bodies) in the
evaluation of an access request [34]. One possibility
would be that the activities of access committees would
be supervised by RECs [10]. The future article 22 § 1 of
the Belgian Act on HBM provides that the aims and the
activities of a biobank have to be reviewed by a REC.
Several informants stressed that access committees and/
or RECs should avail themselves of the necessary expertise
and experience to decide on access requests. An access
committee should comprise representatives from different
medical disciplines (such as pathology and surgery) as well
as clinicians that collected HBM and data for the biobank,
patient representatives and legal, ethical and biomedical ex-
perts. Another important requirement advanced by the in-
formants is the need for profound guarantees that the
committee or body that decides on access requests can act
sufficiently independently from the researcher/principal in-
vestigator who requests access to HBM and data from the
biobank. Such independence could be ascertained by in-
volving one or more external experts in the evaluation of
access requests. One should, of course, make sure that such
an external expert does not have a conflict of interest in the
evaluation of a particular access request. Several authors
shared the opinion that access requests should be decided
upon by independent committees that have the disposal of
the necessary multidisciplinary expertise [10, 34, 35]. This
requirement was motivated by the desire to avoid potential
conflicts [13], to protect the interests, safety and wellbeing
of the donors and to ensure that HBM and data are used in
a meaningful way [35]. Article 19 of the Recommendation
2006 (4) of the Council of Europe [39] contains the require-
ment to establish an independent oversight of population
biobanks, as well as regular audits of the implementation of
the procedures that apply to access to and use HBM. Art-
icle 24 of the Recommendation 2006 (4) stipulates the obli-
gation to conduct an independent examination of the
scientific merit of a research project, the importance of the
aim of research and the verification of the ethical accept-
ability. It should be pointed out, however, that the current
text of Recommendation 2006 (4) only contains rules on
RECs and does not relate to access committees.
Two informants from the Benelux with a legal back-
ground suggested that an equitable and proportionate
set of access criteria could be determined via binding
(national or European) legislation and that the custodian
should only be granted a limited discretionary power to
apply such criteria. They also suggested establishing
some kind of appeal body that could verify whether the
decisions of an access committee apply the access cri-
teria in a non-discriminatory, objective and transparent
manner.
Finally, access committees could be expected to suffi-
ciently motivate their decision and policy.
All informants agreed that no different evaluation cri-
teria should apply for academic and non-academic appli-
cants and for external applicants and applicants affiliated
to the biobank.
Limited right of the custodian to decide on access to
HBM and data
The different conditions that a custodian has to fulfil in
the evaluation of access requests imply that the custo-
dian is not entirely free to decide how to allow access to
his collection of HBM and data. This could be justified
by the fact that the custodians need to guarantee the
protection of the rights and interests of the donor and/
or the applicant. It raises the question whether an appli-
cant could claim a fair or equal right to access and use
of (publicly funded) collections of HBM and data. If such
a right would exist, it would in any case not be absolute.
The applicant can only use HBM and data for a certain
period of time and for a research project that corre-
sponds with the informed consent and the approval by a
REC. It is therefore no surprise that the informants sup-
ported the idea that the custodian could require appli-
cants to provide a short synopsis of the research project.
There was no consensus on the extent to which appli-
cants could be required to submit a more elaborate
protocol with a description of the objective(s), design,
methodology, statistical considerations and organization
of a project. Such a requirement is often applied in the
context of clinical studies on human beings and was sug-
gested in a report of the National Cancer Research Insti-
tute, the National Cancer Intelligence Network and
onCorde UK [37].
The right of the custodian to decide on the fate of
leftover HBM at the end of a project
Table 1 mentions the most important criteria suggested
by informants to decide on the fate of leftover HBM.
Nearly all informants agreed that the applicant should,
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at least, inform the custodian when HBM is leftover at
the end of a project. There was further consensus on the
fact that an applicant that wants to use leftover HBM in
a new or follow-up project, has to submit a new request
or an amendment to the initial request. The access com-
mittee or REC will need to approve such a request or
amendment. All informants also agreed on the fact that
the custodian could prohibit the applicant from transfer-
ring HBM (and data) to a third party (see Table 2). Tak-
ing into account the above, it may be concluded that the
informants recognize the right of the custodian to decide
– whether or not in collaboration with the REC – upon
the fate of leftover HBM.
There was no consensus on the criteria that should
determine whether the biobank should require the re-
turn or destruction of leftover HBM. This may not be
surprising, since other studies revealed that different
policies are applied by biobanks in this respect [23, 39].
Considering the fact that it does not seem possible to
formulate general criteria to decide on the return or de-
struction of leftover HBM, it seems undesirable to regu-
late it through formal legislation. However, biobanks
could clarify in their access arrangements, which criteria
the biobank will take into account to decide on the re-
turn or destruction of leftover HBM, such as the type,
quality, reusability and amount of leftover HBM.
A significant number of informants pointed out that
custodians and applicants tend to agree on the return or
destruction of leftover HBM at the time of the approval
of the access request. This implies that the custodian
would (have to) negotiate with the applicant on a case-
by-case basis on the return or destruction of leftover
HBM. The ‘International Charter of principles for shar-
ing bio-specimens and data,’ however, suggests that
“control of the bio-specimens remains with Provider,
who can at any time demand the return or destruction
of data and bio-specimens if a breach in the agreement
occurs” [34]. The final decision whether to return or
destroy leftover HBM would thus remain with the custo-
dian of the biobank.
Several informants are in favour of a trend to share
HBM only between biobanks and not to provide any
HBM directly to individual researchers. The exclusive ex-
change between biobanks would increase chances that the
HBM and data are stored in a proper way. However, one
should take into account that some individual researchers
are not affiliated to an institution that hosts a biobank.
Some informants pointed out that it would be very
burdensome and difficult – or even impossible – to ver-
ify whether the applicant had returned or destroyed all
leftover HBM. That is why it was argued that return (or
destruction) should be the exception rather than the
rule. Instead, biobanks should – to the extent possible –
divide HBM in different aliquots and provide only the
minimum amount of HBM statistically relevant to ob-
tain a successful outcome. Additional amounts of HBM
could be provided in the course of the project.
The right of biobanks to share in the benefits of a
research project
Several informants suggested that it would be desirable
that some of the benefits of using HBM and data in re-
search projects are returned to the biobank infrastruc-
ture [10, 40]. A custodian of a biobank in Scandinavia
stated the following in this respect:
“I think it’s highly justifiable that some of the financial
benefit that comes out of research based on biobanking
should be fed back into the infrastructure, (…).”
“I need to get money from central sources, and that’s
where I would want some kind of public sector, health-
economic analysis and mechanism to feed some of the
benefit back in. Because if we do it right, there are big
winnings for healthcare authorities.”
All informants seemed to agree that only stakeholders
that provide a scientific contribution might be entitled to
share in the benefits of a research project. Possible scientific
contributions to a research project mentioned during the
interviews were (a) an inventive step; (b) participation or
advice in the development of the research hypothesis,
method or execution of the research project; (c) advice on
the optimal selection and use of HBM and data to respond
to a particular research question; (d) the initial idea or
initiative to collect a particular type of HBM and/or data;
(e) an extensive characterisation of HBM; (f) the develop-
ment of modified HBM (such as cell lines, plasmids); and/
or (h) the preparation and cleaning up of data sets.
Guidelines of the International Committee of Medical
Journal Editors and the Committee on Publications
Ethics only grant authorship to individuals that partici-
pated in “drafting the article or revising it critically for
Table 2 Level of consensus on fate of leftover HBM
Return or destruction No consensus
Re-use Approval of access committee (and REC)
Transfer to third party Approval of access committee (and REC)
Table 1 Overview of criteria suggested by informants to decide
on leftover HBM
Type of HBM
Rare or common HBM
Amount of leftover HBM
Quality and reusability of leftover HBM
Previous experiences and/or collaborations
Cost and complexity of return
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important intellectual content” and “the final approval
of the version to be published” [41]. The provision of
HBM or data for a research project is not considered a
sufficient ground to grant (co-) authorship. In some
cases biobanks may provide important contributions to
research projects via the collection, processing and
organization of unique collections of HBM and data or
the provision of scientific advice or assistance to the pro-
ject. Arguably, the biobank should be recognized for
such contributions [35, 42, 43].
A custodian of a biobank in Scandinavia stated the
following in relation to the importance of biobanks for
biomedical research:
“Make no mistake, that impact of the HPV vaccine
would not have happened at that speed without
biobanks.”
Most informants were sceptical about the idea that the
biobank or the collectors of HBM and data should hold
intellectual property rights (IPRs) on research results.
Nor did they think that the biobank or the collectors of
HBM and data should receive royalties in relation to the
exploitation of such IPRs. A custodian from a biobank in
Scandinavia – with previous experience in the pharma-
ceutical industry – stated the following in this respect:
“For me, with my background, it’s hard to see how a
royalty mechanism would work. Even though biobanks
have compressed the time taken to getting the value,
it’s still a long development time to get a drug to the
market.”
The interviews confirmed that the access fees charged
by biobanks are often not sufficient to recover all costs
in relation to the collection and storage of HBM and
data. The informants agreed that different access/users
fees for public and private or internal and external appli-
cants could be justified by the fact that biobanks are
mostly funded with public investments or by the re-
search institution affiliated to a biobank. Both (aca-
demic) custodians and (industrial) applicants indicated
that an industrial applicant might prefer paying a higher,
but all-inclusive access fee at the beginning of the pro-
ject. A number of authors support the idea of charging
higher access fees to external or industrial applicants
that did not contribute (directly or indirectly) to the col-
lection of HBM and data [4, 38].
Informants in Sweden, Norway and the Netherlands
suggested that applicants that intend to commercialize
the results of a research project would pay a so-called
‘public contribution fee’, i.e., an additional fee or tax
for the use of publicly funded collections of HBM and
data. In return applicants would obtain the right to
(commercially) exploit the potential benefits of their re-
search project. Such a fee would not aim to generate
profits, but to provide a (fair) return for the contribution
of common goods or infrastructure to the commercial-
isation of research projects. One could refer in this re-
spect to public contribution fees or tax charged for the
exploitation of natural resources, such as gas or oil
fields. Public contribution fees might help to avoid dis-
cussions about how important the contribution of a par-
ticular collection of HBM and data was for the final
outcome of the project. The generated fees or taxes
could be dedicated to the funding of public healthcare
and research infrastructure, including biobanks. The
HUGO Ethics Committee recommended in its State-
ment on Benefit Sharing that “profit-making entities
dedicate a percentage (e.g., 1–3 %) of their annual net
profit to healthcare infrastructure and/or to humanitar-
ian efforts.” J. Bovenberg argued in favour of a specific
tax on tissue and cell products directly developed from
HBM and data “as an effective, if indirect, mechanism for
letting a community share in the benefits resulting from
the efforts of the taxpayer concerned and to make a li-
censee pay for the exclusive use of natural resources”
[40]. The author did, however, argue that such a tax
would only be due when a research project resulted in
actual profit for the applicant.
Finally, some informants referred to the Bioresource
Research Impact Factor (BRIF) initiative that aims to
“promote the sharing of bioresources by creating a link
between their initiators or implementers and the impact
of the scientific research using them” [35, 44]. One could
mention that biobanks already publish information on
the research they support and list publications citing re-
search results.
The right of biobanks to share in the benefits of a
research project
The informants agreed that applicants could be requested
to share their research results when they use HBM and
data from publicly funded biobanks (see Table 3). Some
informants doubted whether the custodian should impose
this return of research results as a condition to allow
access to the collection, since this could discourage
researchers from using the collection [45].
Previous studies have confirmed that an increasing num-
ber of biobanks [46] and funding bodies – such as NIH, the
Wellcome Trust and the Dutch cancer association “KWF
Kankerbestrijding” [47] – require researchers to make their
research results publicly available. This requirement is mo-
tivated by the desire to maximize the use of results of pub-
licly funded research [43, 48]. This would certainly be the
case for HBM and data that are quite rare or require a lot
of effort or investment to collect and analyse, such as whole
genome sequencing data. Combining research results from
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different projects may speed up future research and
avoid certain research to be conducted several times.
Access to research results from previous projects could
also allow researchers from multiple disciplines and
with different experience to reinterpret and question
the results. Furthermore, it would make it possible to
study the generated data from new entry points or
perspectives while working on new research questions.
This is particularly important since biomedical re-
search increasingly depends on multidisciplinary ap-
proaches and no researcher or research institute can
avail of all possible expertise. Finally, one can refer to
the fact that an increasing number of scientific journals
require researchers to deposit the raw data of publica-
tions in public databases in order to verify the quality
of research and to avoid fraud.
Another reason for a biobank to require applicants to
share their research results is the possibility to enrich the
collection of HBM and data. The biobank has an interest in
obtaining additional information in relation to the collec-
tion in order to extend the characterization and under-
standing of HBM and data. Information from research
projects could also be used in the future as a basis for the
selection and collection of new data from specific sub-
groups of donors.
Some authors invoke the principle of reciprocity to
justify the obligation to return research results: re-
searchers could be expected to share their results with
stakeholders that have made substantial contributions
to the collection of HBM and data, such as biobanks,
researchers collecting HBM and data and donors [35,
45]. One of the first documents to introduce such a
requirement in the field of genomic research was the
data release policy of the Human Genome project
(HGP), known as the ‘Bermuda Principles’ (1996) [48].
Afterwards, several other international documents pro-
moted sharing research results with other researchers
and the community at large [35], such as the Fort Lau-
derdale Agreement (2003) [49], the OECD Principles
and Guidelines for Access to Research Data from Public
Funding (2007) [26], the Toronto Statement on Pre-
publication Data Sharing (2009) and the Global Alliance
for Genomics and Health’s White Paper (2013) [49].
The majority of the informants agreed that the publica-
tion of the results of research involving HBM and/or data is
in itself insufficient to comply with the obligation to return
or share the research. After all, often only a limited
selection of the research results is actually included in pub-
lications. Several informants were in favour of returning
and/or sharing also negative results of research projects.
Informants indicated that the return of research re-
sults is only useful if a number of conditions are fulfilled.
First, the results must have been managed in a proper
way by the researcher who generated them and sufficient
quality control must have been conducted. Without such
guarantee, it could be dangerous and misleading to use
results from previous research projects. Furthermore, in-
frastructure needs to be available to store the research
results in a proper way and to allow other researchers to
access and use them [50]. Finally, clear rules should be
defined to decide upon requests for access to such re-
search results. Some informants suggested that different
levels of access could be provided to different stake-
holders, such as biobanks, funding agencies and future
researchers.
Another suggestion brought forward by several infor-
mants was to involve the researcher who generated the re-
search results in new research projects. After all, this
researcher formulated the initial research hypothesis and
developed the research protocol and could thus provide
valuable information on how the research results were ob-
tained and how they can be interpreted and used in further
research. As some informants pointed out, it could be diffi-
cult to correctly interpret research results without the ne-
cessary background and knowledge on how the research
results were generated. A custodian in Scandinavia made
the following remark in this respect:
“Raw data can be so vast and enormous, and unless
you understand how to interpret it, itcan be just
meaningless”
The majority of the informants did express the opinion
that the final decision to grant access to research results
should not be taken by the initial researcher, but rather
by the access committee of the biobank or a REC. This
was motivated amongst other reasons by the possibility
that the initial researcher may have a conflict of interest
when deciding whether a new research project – pos-
sibly in the same or similar research domain – should be
allowed to use his research results.
Researchers may be hesitant to share their research
results if they do not receive recognition for their in-
vestments in generating the results [34]. Several au-
thors have pointed out that the legitimate interests of
the researchers and the institutions and funders sup-
porting the project should be respected. Those inter-
ests may be the right to keep some research results
confidential, to obtain IPRs in relation to research re-
sults and a priority right to publish research results
[34, 35, 45, 48].
Table 3 Pre-conditions to share research results
Infrastructure to store and share research results Consensus
Rules on access to research results Consensus
Recognition of researcher that generated results Consensus
Respect interest of researcher that generated results Consensus
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A final point raised by some informants was the
question whether it is desirable or optimal for individ-
ual biobanks to store all research results generated
with their collection of HBM and data. Some suggest
that only biobanks or biobank networks with the
necessary scientific expertise and knowledge may be
suited to store and provide access to research results in
a meaningful way. Others suggested that the research
results would be stored in central research facilities,
such as the European Genome-Phenome Archive (EGA).
Conclusions
The interviews with different stakeholders revealed a rather
complex web of rights and obligations allocated to the cus-
todian and the applicant in relation to access to HBM and
data stored in biobanks and used for research projects. The
results did not allow creating a complete overview of the
rights and obligations that the custodian and the applicant
hold or should hold. Some rights and obligations are nego-
tiated on a case-by-case basis, while others are stipulated in
access arrangements. Furthermore, custodians and appli-
cants can only exercise certain rights when they fulfil par-
ticular obligations and conditions.
There did seem to be a consensus on the attribution of
certain general rights to the custodians and the applicant
(see Table 4). First, the informants agreed that the custodian
of a biobank should be able, under certain conditions, to
decide upon access requests. However, there was no con-
sensus on how extensive the evaluation of an access request
should be and the extent to which the custodian of a bio-
bank should decide upon the scientific merits of an access
request. Second, nearly all informants agreed that a
new request or an amendment to the initial request
has to be submitted when an applicant wants to use
leftover HBM in a new or follow-up project. Third,
the informants agreed that different access fees might
be applied to industrial or external applicants. Fourth,
most informants agreed that a custodian of a biobank
should be able to request the sharing and return of
research results and that some of the benefits of re-
search projects should be fed back into biobanks.
There was no consensus on how the custodian would
exercise such rights in practice and which conditions
they would have to fulfil in this respect.
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